Sage Therapeutics (SAGE) Short Interest Ratio & Short Volume $9.17 +0.02 (+0.22%) Closing price 07/15/2025 04:00 PM EasternExtended Trading$9.15 -0.02 (-0.16%) As of 08:36 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Short Interest Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock Sage Therapeutics Short Interest DataSage Therapeutics (SAGE) has a short interest of 2.81 million shares, representing 5.10% of the float (the number of shares available for trading by the public). This marks a -46.48% decrease in short interest from the previous month. The short interest ratio (days to cover) is 1.8, indicating that it would take 1.8 days of the average trading volume of 1.33 million shares to cover all short positions.Current Short Interest2,810,000 sharesPrevious Short Interest5,250,000 sharesChange Vs. Previous Month-46.48%Dollar Volume Sold Short$25.63 millionShort Interest Ratio1.8 Days to CoverLast Record DateJune 30, 2025Outstanding Shares62,621,000 sharesFloat Size55,090,000 sharesShort Percent of Float5.10%Today's Trading Volume1,068,311 sharesAverage Trading Volume1,327,937 sharesToday's Volume Vs. Average80% Short Selling Sage Therapeutics? Sign up to receive the latest short interest report for Sage Therapeutics and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartSAGE Short Interest Over TimeSAGE Days to Cover Over TimeSAGE Percentage of Float Shorted Over Time Sage Therapeutics Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 6/30/20252,810,000 shares $25.63 million -46.5%5.1%1.8 $9.12 6/15/20255,250,000 shares $35.18 million +1.0%9.5%3.5 $6.70 5/31/20255,200,000 shares $33.80 million +3.8%9.4%5.1 $6.50 5/15/20255,010,000 shares $33.12 million +7.3%9.1%4.4 $6.61 4/30/20254,670,000 shares $34.04 million +7.1%8.5%3.6 $7.29 4/15/20254,360,000 shares $32.87 million +4.6%8.1%3.1 $7.54 3/31/20254,170,000 shares $33.15 million -2.1%7.7%2.2 $7.95 3/15/20254,260,000 shares $32.89 million +8.7%7.9%2.2 $7.72 2/28/20253,920,000 shares $28.62 million -11.1%7.3%2 $7.30 2/15/20254,410,000 shares $31.49 million +5.8%8.2%2.4 $7.14 Get the Latest News and Ratings for SAGE and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Sage Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 1/31/20254,170,000 shares $30.23 million -32.0%7.8%2.4 $7.25 1/15/20256,130,000 shares $44.50 million +26.9%11.7%3.9 $7.26 12/31/20244,830,000 shares $26.23 million -24.7%9.0%4.7 $5.43 12/15/20246,410,000 shares $34.52 million -1.8%11.9%6.8 $5.39 11/30/20246,530,000 shares $35.72 million +1.9%12.1%8.8 $5.47 11/15/20246,410,000 shares $32.69 million +6.8%11.9%8.8 $5.10 10/31/20246,000,000 shares $36.48 million -1.8%11.9%9 $6.08 10/15/20246,110,000 shares $41.91 million +7.0%12.2%9.1 $6.86 9/30/20245,710,000 shares $41.23 million -1.9%11.4%7.7 $7.22 9/15/20245,820,000 shares $45.57 million -6.4%11.6%7.1 $7.83 8/31/20246,220,000 shares $52.43 million +4.9%12.4%6.2 $8.43 8/15/20245,930,000 shares $49.22 million +7.6%11.8%5.6 $8.30 7/31/20245,510,000 shares $60.33 million -1.1%11.0%4.6 $10.95 7/15/20245,570,000 shares $65.73 million -1.8%11.3%4.5 $11.80 6/30/20245,670,000 shares $61.58 million -27.3%11.5%4.4 $10.86 6/15/20247,800,000 shares $93.60 million +12.2%15.8%6.2 $12.00 5/31/20246,950,000 shares $77.21 million -17.9%14.0%6 $11.11 5/15/20248,460,000 shares $99.07 million +3.8%17.1%7.9 $11.71 4/30/20248,150,000 shares $113.61 million -12.5%16.6%7.8 $13.94 4/15/20249,310,000 shares $142.63 million +8.3%19.0%9.2 $15.32 3/31/20248,600,000 shares $161.16 million +2.4%17.5%9.1 $18.74 3/15/20248,400,000 shares $167.75 million +6.2%17.1%9 $19.97 2/29/20247,910,000 shares $169.91 million -12.3%16.1%8.3 $21.48 2/15/20249,020,000 shares $229.20 million +14.8%18.4%9.8 $25.41 1/31/20247,860,000 shares $201.53 million +10.1%15.3%9.1 $25.64 1/15/20247,140,000 shares $189.57 million -4.0%13.9%8 $26.55 12/31/20237,440,000 shares $161.22 million -10.6%14.5%8.6 $21.67 12/15/20238,320,000 shares $180.21 million -3.8%16.2%9.6 $21.66 11/30/20238,650,000 shares $169.37 million -1.7%16.8%8.4 $19.58 11/15/20238,800,000 shares $169.05 million +2.2%17.1%8.1 $19.21Central Banks Are Hoarding Gold – Should You? (Ad)The AI boom isn’t just transforming technology—it’s redefining global power, increasing government debt, and ushering in more economic uncertainty. Claim your FREE AI & Gold Report today and learn what central banks, investors, and analysts are seeing—and how gold can help protect your savings in an uncertain, AI-driven world.▻ Get ahead of the trend—CLICK HERE to claim your FREE AI & Gold Report now! 10/31/20238,610,000 shares $161.27 million -12.8%16.7%7.1 $18.73 10/15/20239,870,000 shares $193.25 million +0.1%19.2%5.6 $19.58 9/30/20239,860,000 shares $202.92 million +3.6%19.2%5.7 $20.58 9/15/20239,520,000 shares $200.11 million +2.7%18.5%5.6 $21.02 8/31/20239,270,000 shares $185.40 million +1.2%18.0%5.9 $20.00 8/15/20239,160,000 shares $194.65 million +27.2%17.8%6.3 $21.25 7/31/20237,200,000 shares $249.70 million +17.5%14.0%5.6 $34.68 7/15/20236,130,000 shares $285.60 million +19.5%12.0%9 $46.59 6/30/20235,130,000 shares $241.21 million -4.8%10.0%8 $47.02 6/15/20235,390,000 shares $302.38 million -0.4%10.5%9.2 $56.10 5/31/20235,410,000 shares $267.80 million -3.6%10.6%10.3 $49.50 5/15/20235,610,000 shares $299.01 million +18.6%10.9%10.6 $53.30 4/30/20234,730,000 shares $231.06 million -2.7%9.2%8.8 $48.85 4/15/20234,860,000 shares $213.69 million +1.5%9.5%9.7 $43.97 3/31/20234,790,000 shares $200.99 million -3.0%9.4%9.3 $41.96 3/15/20234,940,000 shares $214.00 million -4.8%9.7%10 $43.32 2/28/20235,190,000 shares $216.11 million +10.2%10.2%10.5 $41.64 2/15/20234,710,000 shares $212.47 million +2.4%9.2%9.4 $45.11 1/31/20234,600,000 shares $203.96 million +20.1%9.0%9 $44.34 1/15/20233,830,000 shares $174.57 million -8.6%7.5%7.6 $45.58 12/30/20224,190,000 shares $159.81 million +2.7%8.2%8.8 $38.14 12/15/20224,080,000 shares $164.63 million +2.5%8.0%8.4 $40.35 11/30/20223,980,000 shares $163.34 million +7.9%7.8%8.4 $41.04 11/15/20223,690,000 shares $130.07 million -0.5%7.3%8.3 $35.25 10/31/20223,710,000 shares $139.72 million +2.8%7.3%8.5 $37.66 10/15/20223,610,000 shares $136.93 million +0.6%7.1%8 $37.93 9/30/20223,590,000 shares $140.58 million +10.5%7.0%7.9 $39.16 9/15/20223,250,000 shares $137.35 million -9.5%6.4%5.5 $42.26 8/31/20223,590,000 shares $135.20 million +5.6%7.1%5.2 $37.66 8/15/20223,400,000 shares $147.12 million -1.2%6.7%4.5 $43.27 7/31/20223,440,000 shares $118.37 million -3.4%6.8%4.2 $34.41 7/15/20223,560,000 shares $125.49 million -1.9%7.0%4.4 $35.25 6/30/20223,630,000 shares $117.25 million +16.4%7.2%4.3 $32.30 6/15/20223,120,000 shares $101.62 million +9.9%6.2%3.5 $32.57 5/31/20222,840,000 shares $88.81 million -3.4%5.6%4 $31.27 5/15/20222,940,000 shares $90.29 million +1.0%5.8%4.4 $30.71 4/30/20222,910,000 shares $91.72 million +1.8%5.8%4 $31.52 4/15/20222,860,000 shares $100.82 million -6.5%5.7%4.2 $35.25 3/31/20223,060,000 shares $101.29 million -4.7%6.0%4.5 $33.10 3/15/20223,210,000 shares $100.70 million +1.3%6.3%5.4 $31.37 2/28/20223,170,000 shares $115.29 million +18.3%6.3%5.5 $36.37 2/15/20222,680,000 shares $116.58 million -2.6%5.3%4.7 $43.50 1/31/20222,750,000 shares $108.41 million +1.1%5.4%5.9 $39.42 1/15/20222,720,000 shares $116.77 million -1.8%5.3%5.7 $42.93 12/31/20212,770,000 shares $117.84 million -3.2%5.4%5.9 $42.54 12/15/20212,860,000 shares $113.57 million +2.9%5.5%6.1 $39.71 11/30/20212,780,000 shares $108.17 million +2.2%5.4%6 $38.91 11/15/20212,720,000 shares $112.72 million +2.6%5.3%5.9 $41.44 10/29/20212,650,000 shares $106.95 million +6.0%5.1%5.4 $40.36 10/15/20212,500,000 shares $112.35 million +6.8%4.9%4.6 $44.94The End of Elon Musk…? (Ad)The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, and he's been proven right time and time again. And now, while the media focuses on Tesla's "demise," he's uncovered an AI breakthrough that's about to make Elon's doubters eat their words yet again. According to his research, if you listen to the media and miss out on Elon's newest breakthrough, it's going to cost you the fortune of a lifetime.Click here to see why the "End of Elon" crowd is about to be wrong again. 9/30/20212,340,000 shares $103.69 million +23.8%4.5%3.9 $44.31 9/15/20211,890,000 shares $85.01 million -16.4%3.7%2.9 $44.98 8/31/20212,260,000 shares $104.43 million -13.1%4.4%2.4 $46.21 8/13/20212,600,000 shares $113.00 million -23.5%5.1%2.8 $43.46 7/30/20213,400,000 shares $148.68 million -8.9%6.6%3.7 $43.73 7/15/20213,730,000 shares $179.97 million -3.1%7.3%4.4 $48.25 6/30/20213,850,000 shares $218.72 million -7.2%7.5%4.8 $56.81 6/15/20214,150,000 shares $244.02 million -1.0%8.1%5.6 $58.80 5/28/20214,190,000 shares $291.62 million -2.3%8.2%8.9 $69.60 5/14/20214,290,000 shares $297.94 million -4.0%N/A8.8 $69.45 4/30/20214,470,000 shares $352.59 million +1.4%N/A9.3 $78.88 4/15/20214,410,000 shares $333.70 million -2.4%N/A9.1 $75.67 3/31/20214,520,000 shares $331.23 million -11.4%N/A9.1 $73.28 3/15/20215,100,000 shares $401.47 million -1.9%N/A9.7 $78.72 2/26/20215,200,000 shares $433.94 million +2.0%N/A9.4 $83.45 2/12/20215,100,000 shares $426.05 million -1.0%10.0%7.9 $83.54 1/29/20215,150,000 shares $408.24 million -2.7%10.3%7.8 $79.27 1/15/20215,290,000 shares $511.86 million +0.6%10.5%7.8 $96.76 12/31/20205,260,000 shares $466.35 million -0.9%N/A7.5 $88.66 12/15/20205,310,000 shares $375.31 million -2.4%10.6%7.4 $70.68 11/30/20205,440,000 shares $411.10 million +1.7%10.8%7.2 $75.57 11/15/20205,350,000 shares $425.43 million -1.1%10.7%8.4 $79.52 10/30/20205,410,000 shares $399.85 million +6.1%10.8%8.6 $73.91 10/15/20205,100,000 shares $325.84 million -17.9%10.2%7.7 $63.89 9/30/20206,210,000 shares $379.56 million -14.5%12.4%9.4 $61.12 9/15/20207,260,000 shares $424.86 million -3.8%14.5%10.6 $58.52 8/31/20207,550,000 shares $395.92 million +3.9%15.0%10.9 $52.44 8/14/20207,270,000 shares $363.50 million -2.4%14.5%9.9 $50.00 7/31/20207,450,000 shares $339.50 million +3.9%14.6%9.1 $45.57 SAGE Short Interest - Frequently Asked Questions What is Sage Therapeutics' current short interest? Short interest is the volume of Sage Therapeutics shares that have been sold short but have not yet been closed out or covered. As of June 30th, investors have sold 2,810,000 shares of SAGE short. 5.10% of Sage Therapeutics' shares are currently sold short. Learn More on Sage Therapeutics' current short interest. What is a good short interest ratio for Sage Therapeutics? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. SAGE shares currently have a short interest ratio of 2.0. Learn More on Sage Therapeutics's short interest ratio. Which institutional investors are shorting Sage Therapeutics? As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of Sage Therapeutics: Caption Management LLC, and Simplex Trading LLC. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission. What is a good short interest percentage for Sage Therapeutics? Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 5.10% of Sage Therapeutics' floating shares are currently sold short. Is Sage Therapeutics' short interest increasing or decreasing? Sage Therapeutics saw a decline in short interest during the month of June. As of June 30th, there was short interest totaling 2,810,000 shares, a decline of 46.5% from the previous total of 5,250,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. What is Sage Therapeutics' float size? Sage Therapeutics currently has issued a total of 62,621,000 shares. Some of Sage Therapeutics' outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Sage Therapeutics currently has a public float of 55,090,000 shares. How does Sage Therapeutics' short interest compare to its competitors? 5.10% of Sage Therapeutics' shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical products" compare to Sage Therapeutics: Apellis Pharmaceuticals, Inc. (22.25%), NewAmsterdam Pharma Company N.V. (11.06%), Twist Bioscience Corporation (0.05%), Denali Therapeutics Inc. (9.91%), Kiniksa Pharmaceuticals International, plc (6.10%), Agios Pharmaceuticals, Inc. (6.83%), Recursion Pharmaceuticals, Inc. (35.52%), CG Oncology, Inc. (25.16%), Vericel Corporation (4.89%), Beam Therapeutics Inc. (24.82%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: SPDR S&P 500 ETF Trust ($72.10 billion), Invesco QQQ ($26.89 billion), iShares Russell 2000 ETF ($19.61 billion), MicroStrategy Incorporated ($9.52 billion), iShares 20+ Year Treasury Bond ETF ($8.70 billion), WD-40 Company ($7.66 billion), Technology Select Sector SPDR Fund ($6.10 billion), Invesco S&P 500 Equal Weight ETF ($5.80 billion), Invesco S&P 500 Top 50 ETF ($5.53 billion), and Vanguard Large-Cap ETF ($5.35 billion). View all of the most shorted stocks. What does it mean to sell short Sage Therapeutics stock? Short selling SAGE is an investing strategy that aims to generate trading profit from Sage Therapeutics as its price is falling. SAGE shares are trading up $0.02 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Sage Therapeutics? A short squeeze for Sage Therapeutics occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of SAGE, which in turn drives the price of the stock up even further. How often is Sage Therapeutics' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including SAGE, twice per month. The most recent reporting period available is June, 30 2025. More Short Interest Resources from MarketBeat Related Companies Apellis Pharmaceuticals Short Interest Data NewAmsterdam Pharma Short Interest Data Twist Bioscience Short Interest Data Denali Therapeutics Short Interest Data Kiniksa Pharmaceuticals International Short Interest Data Agios Pharmaceuticals Short Interest Data Recursion Pharmaceuticals Short Interest Data CG Oncology Short Interest Data Vericel Short Interest Data Beam Therapeutics Short Interest Data Short Interest Tools Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:SAGE) was last updated on 7/16/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredWhich Gold Miner Trades at 30% of NAV? The One Buffett WantsSome of the world’s best gold developers are trading at just 30% of NAV — like buying a dollar for 30 cents. ...Golden Portfolio | SponsoredWhy Elon is funding the “Quantum Power Grid”Elon knows the future isn’t about smarter AI — it’s about powering it. And this new technology is quietly b...True Market Insiders | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredPost-Halving = Profit Season (Here’s How to Win It)It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredDrilling With a $3.5B Discovery Partner in Its CornerA small-cap explorer is about to drill for high-grade gold in a region known for multi-million-ounce discoveri...The Tomorrow Investor | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sage Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Sage Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
